Even though T-cell-directed trials have been of limited success, is there reason for optimism?

Nature Clinical Practice Rheumatology

Volumn 2, Issue 2, 2006, Pages 58-59

  Panayi, Gabriel S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB DIPHTHERIA TOXIN CONJUGATE; ALEMTUZUMAB RICIN CONJUGATE; ANTIBODY CONJUGATE; CE 9 1; COLLAGEN TYPE 2; CYTOKINE; DIPHTHERIA TOXIN OKT4 CONJUGATE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; KELIXIMAB; LYMPHOKINE; OKT4 RICIN CONJUGATE; PROTEIN DNAJ; PROTEIN DNAJP1; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ACTIVITY; HELPER CELL; HUMAN; IMMUNE RESPONSE; LEUKOCYTOCLASTIC VASCULITIS; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 32644436530     PISSN: 17458382     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncprheum0094     Document Type: Review

References (10)

1. Janossy G et al. (1981) Rheumatoid arthritis: A disease of T-lymphocyte/ macrophage immunoregulation. Lancet 17: 839-842
2. Panayi GS (1995) The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. Agents Actions Suppl 47: 1-21
3. Choy EHS et al. Immunotherapies: T cell, B cell and complement. In Rheumatology, edn 3, 449-454 (Eds Hochberg MC et al.) Philadelphia: Mosby
4. Choy EH et al. (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 41: 1142-1148
5. Mason U et al. (2002) CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 29: 220-229
6. Moreland LW et al. (1998) T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides. Arthritis Rheum 41: 1919-1929
7. Choy EH et al. (2001) Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 44: 1993-1997
8. Prakken BJ et al. (2004) Epitope-specific immunotherapy induces deviation of pro-inflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci 101: 4228-4233
9. Kremer JM et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907-1915
10. Panayi GS (2005) B cell-directed therapy in rheumatoid arthritis - clinical experience. J Rheumatol Suppl 73: 19-24